Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials

D. Chew,Deepak L. Bhatt
DOI: https://doi.org/10.1046/j.1445-5994.2002.00226.x
2002-07-01
Abstract:Recent randomized clinical trials with intravenous glycoprotein IIb/IIIa inhibition have provided unanticipated results, thereby questioning their role as empirical medical management for acute coronary syndromes. The lack of benefit with abciximab observed in Global Utilization of Strategies to Open Occluded Coronary Arteries IV is somewhat inconsistent with the benefits seen with this agent in coronary intervention, and the benefits of an early invasive approach incorporating tirofiban seen within Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy Thrombolysis in Myocardial Infraction 18. Additionally, a direct ‘head‐to‐head’ comparative study of abciximab and tirofiban within the setting of percutaneous coronary intervention demonstrates clinically relevant superiority with abciximab with respect to 30‐day outcomes.
What problem does this paper attempt to address?